Introduction
============

Renal cell carcinoma (RCC) is the most common renal tumor accounting for 2--3% of all malignancies worldwide ([@b1-ol-0-0-10142]). Several histological RCC subtypes have been categorized, and the most frequent subtypes include clear cell RCC (ccRCC), papillary RCC and chromophobe RCC. These subtypes together represent \>90% of all diagnosed RCCs ([@b2-ol-0-0-10142]). Nephrectomy was historically the only treatment option for RCC, with no requirement for advanced prognostication or follow-up. However, since the turn of the century, there have been dramatic changes in the available diagnostics and treatment options ([@b3-ol-0-0-10142]). There is an increasing incidence of detection of small renal tumors (\<40 mm in diameter), primarily due to the increasing use of tomographic radiology, which enables for the improved detection of disease ([@b4-ol-0-0-10142],[@b5-ol-0-0-10142]). Small tumors often grow slowly; however, not all small tumors are indolent in nature ([@b6-ol-0-0-10142]). Several prognostic factors for RCC are presently used in a clinical setting, including tumor stage, Fuhrman grade, lymph node involvement and histological subtype. However, these factors lack accuracy in predicting the natural history of the disease, particularly in patients with non-metastatic disease at the time of diagnosis ([@b7-ol-0-0-10142]).

Overall, 20--30% of all patients with RCC present with metastatic disease at the time of diagnosis, and 20--40% develop metastases following nephrectomy ([@b8-ol-0-0-10142]). The need for prognostic tools in metastatic (m)RCC has also become evident. There are now several available targeted therapies on offer to patients with mRCC in conjunction with metastatic surgery and other ablative therapies of the metastatic lesions. The prognosis of RCC can vary widely, and early detection of recurrence can improve patient outcome, as systemic treatments are more likely to yield a favorable response when the metastatic burden is limited ([@b9-ol-0-0-10142]). Therefore, there is a requirement to identify molecular biomarkers that can aid in predicting patient outcome for patients with RCC, either alone or in combination with the presently used clinical parameters.

MicroRNAs (miRNAs/miRs) are small non-coding RNA molecules that regulate gene expression at a post-transcriptional level ([@b10-ol-0-0-10142]). These molecules serve a key role in a diverse range of biological processes important in cancer development, including proliferation, differentiation and apoptosis ([@b11-ol-0-0-10142],[@b12-ol-0-0-10142]). A single miRNA could alter the expression of a large number of target genes, and therefore has the potential to regulate entire disease-specific pathways and signaling cascades ([@b13-ol-0-0-10142]). Altered miRNA expression has been identified in all human tumors investigated to date, and several diagnostic kits based on miRNA expression profiles are available, including one for the differentiation between histological subtypes of RCC (available from Rosetta Genomics, Ltd., Princeton, NJ, USA). Three of the miRNAs that have previously been suggested as prognostic biomarkers for RCC are miR-21, miR-126 and miR-10b ([@b14-ol-0-0-10142]--[@b21-ol-0-0-10142]). miR-21 is an oncogenic miRNA that has been identified to be upregulated in numerous cancer types, including RCC ([@b14-ol-0-0-10142],[@b15-ol-0-0-10142]). The overexpression of miR-21 increases cell proliferation, migration and invasion, as well as inhibiting apoptosis, and the confirmed target genes for miR-21 are tumor protein p53, phosphatase and tensin homolog, and programmed cell death 4 ([@b22-ol-0-0-10142]--[@b26-ol-0-0-10142]). The deregulation of miR-126 has also been identified in various types of cancer, where it regulates genes involved in the vascular endothelial growth factor and phosphatidylinositol 3-kinase pathways, and therefore serves an important role in processes including angiogenesis and cell cycle regulation ([@b27-ol-0-0-10142]--[@b34-ol-0-0-10142]). The third miRNA, miR-10b, has previously been reported as an oncomiR in specific types of cancer, while it has been reported to exert a tumor suppressor role in others, among them RCC ([@b16-ol-0-0-10142],[@b35-ol-0-0-10142]--[@b38-ol-0-0-10142]). The overexpression of miR-10b in RCC cell lines inhibits cell proliferation, migration and invasion; however, the exact mechanism has not been completely elucidated ([@b17-ol-0-0-10142],[@b38-ol-0-0-10142]). Even though the expression of these 3 miRNAs have previously been investigated in RCC, their use as prognostic biomarkers for this disease remains debatable. Therefore, further studies are required in order to validate their potential to predict clinical outcome in patients with RCC.

The present study aimed to investigate and validate the value of miR-126, miR-21 and miR-10b expression as prognostic biomarkers in a Swedish cohort of patients with RCC. An additional aim was to identify the most suitable endogenous control gene(s) for miRNA expression studies in ccRCC tissues.

Materials and methods
=====================

### Study population

Patients were recruited from the Örebro Kidney Cancer Cohort (OKCC), which consisted of 485 patients consecutively diagnosed with RCC, who received surgical treatment between January 1, 1986 and December 31, 2013 at the Department of Urology, Örebro University Hospital, Örebro, Sweden. The patients were followed through medical records until December 31, 2015 and, in cases where the patient was deceased, the cause of mortality was established by the death certificate from the Swedish Cause of Death Register and classified as mortality from renal cancer or from other causes. The inclusion criteria for the present study were a diagnosis of ccRCC and the undergoing of surgery for RCC between 1986 and 2010. Of the initial 485 patients in the OKCC cohort, 221 patients were excluded from the study (92 had surgery after 2010, 42 had no tumor sample available for histological re-evaluation, 6 had benign tumor at histological re-evaluation, and 81 had other tumor histology than ccRCC), leaving 264 patients matching the inclusion and exclusion criteria. Due to the limited amount of tissue available from these patients, 116 were randomly selected for inclusion in the present study. Of these 116 patients, 69 had malignant and adjacent benign tissue available for nucleic acid extraction, and the remaining 47 patients had only malignant tissue available for extraction ([Fig. 1](#f1-ol-0-0-10142){ref-type="fig"}). The selected patient characteristics are listed in [Table I](#tI-ol-0-0-10142){ref-type="table"}. The present study was approved by the ethics committee of the Uppsala and Örebro region, Sweden.

### Stability of endogenous control genes

In order to determine which endogenous control genes were the most suitable for miRNA expression studies in ccRCC, a subset of 21 samples were chosen to investigate the stability of 7 previously reported control genes for renal tissues. The samples were chosen to span across all years (1987--2010) and to include various tumor stages and grades ([Table II](#tII-ol-0-0-10142){ref-type="table"}). Malignant and adjacent benign tissues were included in the investigation (n=42).

### Nucleic acid extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The patient material in the present study consisted of formalin-fixed paraffin-embedded (FFPE) tissue obtained from patients with ccRCC. Malignant and adjacent benign tissue was marked by two dedicated uro-pathologists (MF and FG) on hematoxylin and eosin slides corresponding with the paraffin blocks prior to punching out two cores (1 mm) of tissue from each area. The tissue cores were deparaffinized according to a standard protocol using xylene and alcohols prior to the extraction of DNA and total RNA (including small RNAs) using the AllPrep DNA/RNA FFPE kit (catalog no. 80234; Qiagen GmbH, Hilden, Germany), according to the manufacturer\'s protocol. The quality and quantity of the resulting DNA and RNA was assessed using the NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The RNA quality was determined using the 2100 BioAnalyzer system with the RNA 6000 Pico kit (Agilent Technologies, Santa Clara, CA, USA). Total RNA samples were diluted to a concentration of 2 ng/µl prior to RT using the TaqMan^®^ microRNA reverse transcription kit (catalog no. 4366596; Thermo Fisher Scientific, Inc.) and TaqMan^®^ assays specific for the miRNAs and endogenous control genes investigated in the present study. The thermal protocol used for RT was as follows: 16°C for 30 min, 42°C for 30 and 5 min at 85°C. The resulting cDNA was mixed with TaqMan^®^ universal master mix II no AmpErase^®^ UNG (catalog no. 4440040; Thermo Fisher Scientific, Inc.) and TaqMan^®^ small RNA assays specific for each miRNA and endogenous control gene ([Table III](#tIII-ol-0-0-10142){ref-type="table"}), and used in qPCRs, according to the manufacturer\'s protocol. The thermocycling conditions for qPCR were as follows: 95°C for 10 min, 40 cycles of 95°C for 15 sec and 60°C for 1 min. All reactions were performed on an Applied Biosystems 7900HT real-time PCR system and raw C~q~ values were determined using SDS software version 2.4 (both Applied Biosystems; Thermo Fisher Scientific, Inc.). A threshold of 0.2 was used for each miRNA.

### Statistical analysis

The stability of the endogenous control genes was evaluated using NormFinder ([@b39-ol-0-0-10142]). This software application calculates a stability value (SV) defined as the absolute mean + one standard deviation; which is calculated using the intergroup variation values from the candidate control genes. Raw C~q~ values were used as input. A Wilcoxon signed rank test was performed for the comparison of the expression levels of the endogenous control genes between malignant and adjacent benign samples.

All samples were analyzed in four replicates, and the mean C~q~ value was calculated and used in subsequent analyses. In order to compare the miRNA expression levels between malignant and adjacent benign tissues, a Wilcoxon test was performed. The relative up- or downregulation (fold change, FC) of miRNAs in malignant tissue compared with adjacent benign tissue was obtained by 2^−∆∆Cq^ method ([@b40-ol-0-0-10142]), assuming complete efficiency of the qPCR. A Mann-Whitney U test or Kruskal-Wallis test with the ∆C~q~ values as input values were subsequently used to compare miRNA expression levels between groups of patients. The miRNA expression was divided into high or low expression based on receiver operating characteristic (ROC) curves with disease-specific survival as the endpoint. The Kaplan-Meier method was used to estimate survival probabilities and the log-rank test was used to compare groups. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of the association between miRNA expression and time to recurrence of the disease and disease-specific survival. Person-time was calculated from the date of cancer diagnosis to the earliest of the following time points: Either mortality from renal cancer or the recurrence of the disease (depending on the endpoint of the analysis), censored at time of mortality from other causes, or the end of follow-up (December 2015). Cox regression models were performed using miRNAs as dichotomous variables, adjusting for primary tumor diameter (\<40 vs. \>40 mm), American Joint Committee on Cancer (AJCC) stage (I+II vs. III+IV) and Fuhrman grade (I+II vs. III+IV) ([@b41-ol-0-0-10142],[@b42-ol-0-0-10142]). In order to evaluate the discriminating capacities of each miRNA, alone or in combination with other predictive factors, ROC curve analyses were performed with a calculation of the area under the curve (AUC) for disease-specific survival. P\<0.05 was considered to indicate a statistically significance. All analyses were performed in SPSS version 22.0 (IBM Corp., Armonk, NY, USA).

Results
=======

### Endogenous control genes

In order to investigate whether the endogenous control genes used in the present study were stably expressed across all samples, stability tests were performed on 7 endogenous control genes (RNU44, RNU24, RNU48, RNU6B, U6, U47 and RPL21) in 21 paired malignant and adjacent benign renal tissue samples. No significant difference in the expression between malignant and adjacent benign tissue for any of the control genes tested was identified ([Table II](#tII-ol-0-0-10142){ref-type="table"}). The NormFinder software application identified RNU48 (SV, 0.005), U47 (SV, 0.011) and the combination of RNU48 and U47 (SV, 0.006) as the most stably expressed endogenous control genes within these samples ([Table IV](#tIV-ol-0-0-10142){ref-type="table"}).

### miRNA expression profiles differentiate between malignant and adjacent benign tissues

Based on the results from the investigation of endogenous control genes, the miRNA expression values were normalized to the geometric mean of RNU48 and U47. The expression levels of miR-126, miR-21 and miR-10b were investigated in 69 paired samples of malignant and adjacent benign tissues. A difference in the expression between the malignant and benign tissues was evident for all three miRNAs, with miR-126 (P=0.004) and miR-21 (P\<0.001) being upregulated, and miR-10b (P\<0.001) being downregulated in malignant tissues compared with adjacent benign tissue samples ([Fig. 2](#f2-ol-0-0-10142){ref-type="fig"}). Heterogeneity in the up/downregulation of the miRNAs in the samples was also identified. miR-126 was upregulated in 46 of the 69 (66.7%) malignant samples with a median FC of 3.25 (range, 1.05--66.64). A more consistent upregulation was identified for miR-21, which was upregulated in 62 of the 69 (89.8%) samples, with a median FC of 5.95 (range, 1.21--305.57). miR-10b was downregulated in 48 of the 69 (69.6%) malignant samples, with a median FC of 0.37 (range, 0.01--0.98) in the downregulated samples.

### miRNA expression profiles as prognostic biomarkers

The expression of miR-126, miR-21 and miR-10b was subsequently investigated in 116 ccRCC tumor specimens from the OKCC. miR-10b downregulation was associated with increasing AJCC stage (I+II vs. III+IV; P\<0.001) and Fuhrman grade (I+II vs. III+IV; P\<0.001). However, no difference was observed in the expression of miR-10b in the samples of patients presenting with metastatic disease at the time of diagnosis compared with that in patients without metastases (P=0.07). miR-126 downregulation was also more prominent with increasing AJCC stage (I+II vs. III+IV, P\<0.001) and Fuhrman grade (I+II vs. III+IV, P\<0.001), and a difference in expression was identified in patients with metastases at the time of diagnosis compared with that in patients without metastases (P=0.036). The expression of miR-21 was not associated with any of the clinical variables investigated in the present study, including AJCC stage, Fuhrman grade or metastatic disease at the time of diagnosis.

The expression levels of the investigated miRNAs were subsequently divided into low and high expression groups using ROC curves. Disease-specific survival time following diagnosis in the miR-126 low and high groups were 87.8±11.7 and 138.9±17.5 months, respectively (P=0.012; [Fig. 3A](#f3-ol-0-0-10142){ref-type="fig"}). Patients with low miR-126 expression also had shorter time to recurrence of disease, compared with that of patients with high miR-126 expression, 124.9±17.9 and 155.4±13.9 months, respectively (P=0.007; [Fig. 3B](#f3-ol-0-0-10142){ref-type="fig"}). No differences in the time to recurrence or disease-specific survival were identified between the low and high miR-10b or miR-21 expression groups (P\>0.05).

In the multivariate analysis, the patients with low miR-126 expression tended to exhibit a shorter recurrence time compared with that of patients with high expression (adjusted HR, 1.79; 95% CI, 0.91--3.52). Patients with low miR-126 expression also tended to exhibit shorter disease-specific survival time (adjusted HR, 1.94; 95% CI, 0.95--3.97) ([Table V](#tV-ol-0-0-10142){ref-type="table"}). Neither miR-10b nor miR-21 expression (low versus high) was associated with recurrence or disease-specific survival times.

In order to explore the accuracy of miRNA expression and the presently used prognostic factors (Fuhrman grade, AJCC stage and primary tumor diameter) as classifiers of lethal renal cancer, ROC curves were employed. The baseline model, including Fuhrman grade, AJCC stage and primary tumor diameter, yielded an AUC of 0.73 (95% CI, 0.63--0.83). Adding the dichotomized (low versus high) expression of miR-126 yielded an insignificant increase of the AUC (AUC, 0.754; 95% CI, 0.66--0.85; P\>0.05). Including the dichotomized expression of all three miRNAs further increased the AUC (AUC, 0.77; 95% CI, 0.67--0.87; P\>0.05; [Fig. 4](#f4-ol-0-0-10142){ref-type="fig"}); however, this increase was not statistically significant. No single threshold for any measurement of the combined model yielded high sensitivity combined with high specificity.

### Subgroup analysis

In order to investigate whether the expression of miR-126, miR-21 or miR-10b may be used as reliable biomarkers for aggressive disease in patients with a primary tumor diameter of ≤40 mm, a subgroup analysis was performed. Patients with a primary tumor diameter of \>40 mm and low miR-126 expression exhibited shorter recurrence time (P=0.035) and disease-specific survival time (P=0.028), compared with patients with high expression. However, no difference in the time to disease recurrence or disease-specific mortality were identified between patients with low or high miR-126 expression who had a primary tumor diameter \<40 mm. When adjusting for other clinical parameters, no association between miR-126 expression and time to recurrence or disease-specific mortality was observed in patients with a primary tumor diameter of \<40 nor \>40 mm.

Discussion
==========

Previous studies have investigated the potential role of miRNAs as biomarkers for RCC (14,15,17-21,23,43-50). However, the value of using miRNAs as prognostic biomarkers for RCC is still under debate. The present study selected the miRNAs miR-126, miR-21, and miR-10b, which have previously been suggested as prognostic biomarkers for RCC, and aimed to validate their usefulness as prognostic markers in a Swedish cohort of patients with RCC. The results of the present study demonstrated that all three miRNAs were deregulated in malignant tissues when compared with adjacent benign tissues. However, the present study could only confirm a potential prognostic value for the expression of miR-126, but not for that of miR-21 or miR-10b.

In order to minimize the influence of technical variation and to increase the expression accuracy of biological data, the normalization of gene expression data is required. Due to the low number of target genes investigated, population-based normalization methods commonly used in microarray studies are not suitable for qPCR data, and normalization is instead dependent on the use of endogenous control genes as references for normal expression ([@b51-ol-0-0-10142]). No universal control gene suitable for all experiments exists, and it has previously been recommended to test the most suitable control gene specific for the experiment performed ([@b52-ol-0-0-10142]). A total of seven candidate control genes for miRNA expression studies in FFPE tissues from patients with ccRCC were investigated in the present study. The results indicate that RNU48, followed by U47, or the combination of these genes, were the most suitable for normalization of miRNA expression within the present study. Since normalization based on a single control gene could lead to erroneous results, the use of multiple control genes for normalization is preferred ([@b52-ol-0-0-10142],[@b53-ol-0-0-10142]). Therefore, the normalization of the RT-qPCR data in the present study was performed using the geometric mean of RNU48 and U47 expression.

The deregulation of miR-126 has been identified in a variety of cancer types; however, its role in carcinogenesis remains to be elucidated. The expression of miR-126 has been observed to be downregulated in lung and esophageal cancer ([@b27-ol-0-0-10142],[@b28-ol-0-0-10142]). On the other hand, the same miRNA has been identified to be upregulated in urothelial and gastric cancer ([@b29-ol-0-0-10142],[@b30-ol-0-0-10142]). In RCC, the expression of miR-126 has been reported to serve a role in the molecular classification of histological subtypes ([@b54-ol-0-0-10142]). The results of the present study demonstrate that miR-126 was upregulated in ccRCC, and that the expression of miR-126 was decreased with increasing grade and tumor stage, which is consistent with previous findings for RCC ([@b15-ol-0-0-10142],[@b19-ol-0-0-10142],[@b20-ol-0-0-10142],[@b49-ol-0-0-10142]). However, the present study observed a heterogeneity of miR-126 expression in malignant samples, being upregulated in 66.7% and downregulated in 33.3% of the investigated samples. Similar findings were observed by Vergho *et al* ([@b15-ol-0-0-10142]), who hypothesized that miR-126 was up/downregulated in different subgroups of patients with RCC. The same authors later reported a downregulation of miR-126 in ccRCC cases with tumor thrombus of the inferior vena cava, but not in cases without tumor thrombus ([@b20-ol-0-0-10142]). These results suggest that the downregulation of miR-126 in the primary tumor is associated with a more invasive phenotype. This hypothesis is supported by the data of others including those of the present study, demonstrating that patients with metastatic disease at the time of diagnosis have lower miR-126 expression in the primary tumor compared with patients presenting without metastases at diagnosis ([@b15-ol-0-0-10142],[@b19-ol-0-0-10142],[@b20-ol-0-0-10142],[@b48-ol-0-0-10142],[@b49-ol-0-0-10142]). A low miR-126 expression was also associated with early recurrence and shorter disease-specific survival time in the univariate, but not multivariate, analyses, which was also consistent with results obtained from previous studies ([@b15-ol-0-0-10142],[@b20-ol-0-0-10142],[@b47-ol-0-0-10142]). A ROC analysis indicated that the addition of miR-126 expression to currently used clinical factors could improve the prognostic accuracy. However, this small increase in AUC may not easily translate to the clinical setting.

An early event in the pathogenesis of RCC is the inactivation of the tumor suppressor Von Hippel-Lindau (*VHL*), which is a direct target gene of miR-21 ([@b55-ol-0-0-10142]). As the downregulation of *VHL* may be caused by the upregulation of miR-21, the deregulation of miR-21 could constitute an early event in renal carcinogenesis. Several studies have demonstrated that miR-21 is overexpressed in renal tumors compared with benign renal tissue ([@b14-ol-0-0-10142],[@b15-ol-0-0-10142],[@b20-ol-0-0-10142],[@b21-ol-0-0-10142],[@b44-ol-0-0-10142],[@b46-ol-0-0-10142],[@b49-ol-0-0-10142],[@b50-ol-0-0-10142]). In the present study, miR-21 was identified to be upregulated in 89.8% of the ccRCC tissues, in line with a study performed by Zaman *et al* ([@b21-ol-0-0-10142]), who reported miR-21 upregulation in 89% of the investigated renal tumors. Previous studies have also observed an increased expression of miR-21 in increasing grades and stages of RCC ([@b14-ol-0-0-10142],[@b15-ol-0-0-10142]), and that patients with metastatic disease at the time of diagnosis had a higher expression of miR-21 in their primary tumor ([@b14-ol-0-0-10142],[@b15-ol-0-0-10142],[@b20-ol-0-0-10142],[@b21-ol-0-0-10142],[@b49-ol-0-0-10142]). However, these results could not be confirmed in the present study, as no association between miR-21 expression and tumor grade, stage or patient outcome was identified.

miR-10b is considered to be associated with the metastatic behavior of tumors, partly due to its role as a suppressor of homeobox D10, a transcriptional repressor that inhibits expression of genes involved in cell migration and extracellular matrix remodeling ([@b56-ol-0-0-10142]). In the present study, miR-10b was observed to be downregulated in ccRCC tissues compared with adjacent benign tissue, a finding supported by previous studies ([@b18-ol-0-0-10142],[@b44-ol-0-0-10142],[@b46-ol-0-0-10142],[@b49-ol-0-0-10142]). This investigation did not reveal a difference in the expression of miR-10b between patients presenting with or without metastatic disease at the time of diagnosis. However, several studies have reported miR-10b as one of the most downregulated miRNAs in metastatic tissue, with a gradual downregulation of the expression between normal tissue, primary tumor and metastatic tissue ([@b43-ol-0-0-10142],[@b48-ol-0-0-10142],[@b49-ol-0-0-10142]). Patients with a high expression of miR-10b have previously been demonstrated to have longer progression-free and disease-free survival times ([@b18-ol-0-0-10142],[@b42-ol-0-0-10142]). This could not be confirmed in the present study, as no association between miR-10b expression and clinical outcome was evident.

The discrepancies between the results of the present study and previous studies may be due to a number of factors, including differences in patient populations, timing and method of tissue sampling, and the use of fresh-frozen or FFPE tissue. Furthermore, the analysis method (microarray, qPCR or next generation sequencing), or choice of endogenous control genes for normalization of qPCR data may also influence the results of a study. A strength of the present study is the investigation of endogenous control genes within the cohort. Numerous studies use constitutively expressed housekeeping genes for normalization, without proper validation of their presumed stability of expression, which may produce erroneous results. If miRNAs are to be used as biomarkers for RCC, a standardized analysis scheme should be optimized for all these variables.

Another strength of the present study is the well-defined cohort used, including complete follow-up of the study participants, with well defined outcome measurements from the Swedish Cause of Death register. Many of the previously performed studies have limitations due to relatively short follow-up periods of the patients. A caveat within this study is that due to the relatively small study population, there was not enough statistical power to investigate the prognostic potential of miRNA expression in subgroups of patients (e.g., metastatic versus non-metastatic disease). Therefore, additional studies are required to further explore the prognostic potential of miRNA expression in subgroups of patients with ccRCC. Furthermore, only three of almost 2,000 known miRNAs were investigated in the present study, which limits the opportunity to identify novel potential prognostic biomarkers for ccRCC.

To conclude, several prognostic factors for RCC are presently being used in a clinical setting; however, these factors lack accuracy in predicting the natural history of the disease, particularly in patients with non-metastatic disease at the time of diagnosis. Therefore, the identification of biomarkers that can aid in predicting patient outcome for patients with RCC, either alone or in combination with currently used clinical parameters are required. The results of the present study confirm that all of the investigated miRNAs are deregulated in malignant tissue compared with adjacent benign tissue. However, only one of the miRNAs investigated, miR-126, exhibited prognostic potential among the included patients.
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![The Örebro Kidney Cancer Cohort consists of 485 patients undergoing surgery for renal cancer at the University Hospital of Örebro between 1986 and 2013. From this cohort 221 patients were excluded from the current study; 92 were excluded due to undergoing surgery after 2010, 42 did not have tumor tissue available for histological re-evaluation, 6 were diagnosed with a benign renal tumor at re-evaluation, and 81 had histological subtypes of renal cancer other than ccRCC. From the remaining 264 patients, 116 patients were randomly chosen for inclusion in the final study cohort. Of these patients, tumor as well as adjacent benign tissue was available for nucleic acid extraction from 69 patients, and from the remaining 47, only tumor tissue was available. ccRCC, clear cell renal cell carcinoma.](ol-17-05-4566-g00){#f1-ol-0-0-10142}

![Box-plots of the expression of three miRNAs in malignant and adjacent benign renal tissue. The whiskers indicate minimum and maximum ΔC~q~ values for each tissue type. (A) miR-126 is upregulated, (B) miR-21 is upregulated, and (C) miR-10b is downregulated in malignant renal tissue compared with adjacent benign tissue. \*\*P\<0.01 and \*\*\*P\<0.001. miR/miRNA, microRNA.](ol-17-05-4566-g01){#f2-ol-0-0-10142}

![Kaplan-Meier survival plots of miR-126 expression (low vs. high). (A) Disease-specific survival and (B) recurrence of the disease, among patients diagnosed with clear cell renal cell carcinoma between 1987 and 2010 within the Örebro Kidney Cancer Cohort. miR, microRNA.](ol-17-05-4566-g02){#f3-ol-0-0-10142}

![Receiver operating characteristics analysis of prognostic factors for renal cell carcinoma. The base model includes American Joint Committee on Cancer stage, Fuhrman grade and primary tumor diameter (\>40 vs. \<40 mm). Adding dichotomized miR-126 expression (low vs. high) increased the AUC compared to using only the base model (AUC, 0.754 vs. AUC, 0.73; P\>0.05). Including the expression of miR-126, miR-21 and miR-10b (high vs. low) also increased the AUC compared to using only the base model (AUC, 0.77 vs. AUC, 0.73; P\>0.05). miR, microRNA; AUC, are under the curve.](ol-17-05-4566-g03){#f4-ol-0-0-10142}

###### 

Selected patient demographic and clinical characteristics (n=116).

  Characteristics                             Value
  ------------------------------------------- -------------------
  Mean age at diagnosis (range), years        66.9 (40--93)
  Sex, n (%)                                  
    Male                                      62 (53.4)
    Female                                    54 (46.6)
  Mean BMI at diagnosis (range)               27.1 (18.1--39.5)
  Smoking status, n (%)                       
    Yes                                       35 (30.2)
    No                                        52 (44.8)
    Missing                                   29 (25.0)
  Median primary tumor diameter (range), mm     70 (20--160)
  AJCC stage                                  
    I                                         49 (42.2)
    II                                        24 (20.7)
    III                                       26 (22.4)
    IV                                        17 (14.7)
  Fuhrman grade                               
    I                                         4 (3.4)
    II                                        52 (44.8)
    III                                       48 (41.4)
    IV                                        12 (10.3)
  Metastases at diagnosis                     
    Yes                                         14 (12.1)
    No                                        102 (87.9)
  Radical nephrectomy                         
    Yes                                       107 (92.2)
    No                                          9 (7.8)
  Partial nephrectomy                         
    Yes                                       10 (8.6)
    No                                        106 (91.4)
  Recurrence                                  
    Yes                                       49 (42.2)
    No                                        67 (57.8)
  Cause of mortality                          
    Renal cancer                              48 (51.1)
    Other cause                               46 (48.9)
    Alive                                     22
  Median follow-up time (range), months         63 (0--302)

BMI, Body Mass Index; AJCC, American Joint Committee on Cancer.

###### 

Clinicopathological features of samples included in the selection of endogenous control genes.

  Sample^[a](#tfn2-ol-0-0-10142){ref-type="table-fn"}^   Year of diagnosis   Fuhrman grade   AJCC stage
  ------------------------------------------------------ ------------------- --------------- ------------
    1                                                    1989                IV              IV
    2                                                    1990                II              I
    3                                                    1991                III             IV
    4                                                    1992                II              II
    5                                                    1993                III             IV
    6                                                    1994                II              II
    7                                                    1995                II              III
    8                                                    1996                III             IV
    9                                                    1997                II              I
  10                                                     1998                IV              III
  11                                                     1999                II              I
  12                                                     2000                III             III
  13                                                     2001                II              I
  14                                                     2002                III             III
  15                                                     2003                II              I
  16                                                     2004                III             IV
  17                                                     2005                II              I
  18                                                     2006                III             IV
  19                                                     2007                II              IV
  20                                                     2008                II              I
  21                                                     2009                III             II

For each patient, malignant and adjacent benign tissue were used (n=42). AJCC, American Joint Committee on Cancer.

###### 

Control genes and miRs investigated in the present study.

  Name^[a](#tfn3-ol-0-0-10142){ref-type="table-fn"}^   TaqMan assay^[b](#tfn4-ol-0-0-10142){ref-type="table-fn"}^   ID^[c](#tfn5-ol-0-0-10142){ref-type="table-fn"}^
  ---------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------
  RNU44                                                001094                                                       NR_002750
  RNU24                                                001001                                                       NR_002447
  RNU48                                                001006                                                       NR_002745
  RNU6B                                                001093                                                       NR_002752
  U6                                                   001973                                                       NR_004394
  U47                                                  001223                                                       AF141346
  RPL21                                                001209                                                       AB061826
  miR-126                                              002228                                                       hsa-miR-126-3p
  miR-21                                               000397                                                       hsa-miR-21-5p
  miR-10b                                              002218                                                       hsa-miR-10b-5p

Control gene or miR name.

Assay ID from Thermo Fisher Scientific, Inc.

National Center for Biotechnology Information accession no. for the control genes, and miRBase ID for the miRs. miR, microRNA.

###### 

Stability analysis of endogenous control genes with the NormFinder software.

  Control gene^[a](#tfn6-ol-0-0-10142){ref-type="table-fn"}^   SV      SE      N
  ------------------------------------------------------------ ------- ------- ----
  RNU44                                                        0.016   0.006   42
  RNU24                                                        0.013   0.005   42
  RNU48^[b](#tfn7-ol-0-0-10142){ref-type="table-fn"}^          0.005   0.004   42
  RNU6B                                                        0.014   0.004   42
  U6                                                           0.018   0.007   42
  U47^[b](#tfn7-ol-0-0-10142){ref-type="table-fn"}^            0.01    0.005   42
  RPL21                                                        0.016   0.006   42

20 degrees of freedom and P≥0.05 for all, using Wilcoxon test.

Identified as the two most stable controls and the best combination of two genes with an SV of 0.006. SE, standard error; SV, stability value; N, number of samples.

###### 

Cox regression analysis of low versus high miR-126 expression.

                              HR (95% CI)         
  --------------------------- ------------------- -------------------
  Disease recurrence          2.32 (1.23--4.38)   1.79 (0.91--3.52)
  Disease-specific survival   2.32 (1.18--4.55)   1.94 (0.95--3.97)

Adjusted for primary tumor diameter (\<40 vs. \>40 mm), American Joint Committee on Cancer stage (I+II vs. III+IV) and Fuhrman grade (I+II vs. III+IV). miR, microRNA; HR, hazard ratio; CI, confidence interval.
